Adam J. Gadzinski, MD, MS, on the Research Coming Out of SUO This Year

Video

Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and acting clinical instructor in the Department of Urology at the University of Washington, discussed what is most exciting about the research being presented this year at the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

Transcription:

I think a lot of the discussions have been around some of the new systemic treatments in prostate cancer and the genomic mutations in prostate cancer and how those are just now starting to guide our therapies for advanced prostate cancer. That's a very exciting place.

In the last 10 years, there's been numerous advances in men with metastatic prostate cancer. For decades, it was hormone suppression, whether that was achieved with shots or removing the testicles, and that was it. And now we're kind of an embarrassment of riches, and we keep getting more and now we're finding which specific ones work best for which specific patients with a subtype of cancer. So now we can accurately say we're getting to the personalized medicine that we've been talking a lot about for the last 20 years. We're finally getting there now.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content